Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment

"We see, based on these subgroup analysis, that patients do really well, but for patients who are heavily treated with5 or more lines of prior treatment, I think, given that the liso-cel efficacy goes slightly lower, it's really important to keep bringing these constructs ahead in the algorithm for managing management of mantle cell lymphoma, because so far, it remains a fairly heterogeneous disease. It is certainly treatable but there are definitely not many cures out there, so I do believe that it's important that constructs like liso-cel, if brought early on, will show better efficacy and thus better duration of remission, thus better progression free survival, and then hopefully better overall survival.”

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy FDA-approved for patients with heavily pretreated mantle cell lymphoma, has demonstrated its ability to yield durable complete responses for this indication.¹ Subgroup analyses of outcomes after liso-cel in these patients were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois.² The subgroup analyses were conducted according to prior lines of therapy and prior Bruton tyrosine kinase inhibitor treatment.

CGTLive® spoke with study coauthor Manali Kamdar, MD, to learn more about the findings from the subanalyses. She emphasized that given the lower efficacy seen in patients with 5 prior median lines of therapy, it is important to bring liso-cel to earlier lines of treatment.

REFERENCES

1. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. News release. FDA. May 30, 2024. Accessed May 30, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma
2. Palomba ML, Siddiqi T, Gordon LI, et al. Lisocabtagenemaraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL). Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7016